CG Oncology Earnings Call Transcripts
Fiscal Year 2026
-
Credo demonstrates strong efficacy and durability in multiple bladder cancer settings, with a 75.5% CR rate in BOND-003 and promising adjuvant and combination data. Regulatory filings are underway, with commercial launch preparations targeting a concentrated market and leveraging a robust team.
-
The session highlighted strong clinical progress for a novel bladder-sparing immunotherapy, with pivotal trials in both high-risk and intermediate-risk NMIBC nearing key data readouts. The therapy shows best-in-class efficacy, safety, and commercial readiness, with regulatory submissions and market expansion planned through 2027.
Fiscal Year 2025
-
The session highlighted strong two-year response and durability data for CReDO in BCG-unresponsive NMIBC, a robust regulatory and manufacturing strategy, and plans to establish CReDO as backbone therapy across multiple bladder cancer segments. Upcoming pivotal data and a solid cash position support future growth.
-
Significant progress was reported in late-stage clinical trials for NMIBC, including strong 24-month efficacy data and accelerated trial enrollment. Regulatory and manufacturing strategies are focused on CMC readiness and streamlined administration, while commercial plans target unmet needs in high-volume centers.
-
Significant progress in non-muscle invasive bladder cancer with strong clinical data, streamlined administration, and a robust commercial strategy targeting high-volume accounts. BLA filing is on track for year-end, supported by a solid cash position and multiple upcoming data readouts.
-
Cretostimogene demonstrated strong durability and tolerability in high-risk NMIBC, with 46% 12-month and 34% 24-month CR rates, and 97.3% cystectomy-free survival at 24 months. Regulatory filing is planned for H2 2025, and the company is well-financed through 2028.
-
Phase 3 data for cretostimogene in high-risk BCG-unresponsive non-muscle-invasive bladder cancer show a 75.5% complete response rate, class-leading durability, and a favorable safety profile. The therapy is easily administered, with ongoing trials in additional settings and combinations.
-
Focused on bladder-sparing therapies for NMIBC, the program shows strong efficacy, durability, and safety, with a robust regulatory and commercial strategy targeting a large, concentrated U.S. market. Multiple pivotal data readouts and a BLA submission are expected later this year.
Fiscal Year 2024
-
BOND-003 phase 3 results show cretostimogene grenadenorep achieved a 74.5% complete response rate in BCG-unresponsive, high-risk NMIBC, with durable responses exceeding 27 months and a favorable safety profile. Efficacy was consistent across subgroups, and the therapy integrates easily into clinical practice.
-
Cretostimogene shows high response and safety in bladder cancer, with pivotal data expected year-end. Manufacturing and logistics improvements support broad adoption, while new trials address unmet needs due to BCG shortages. Key regulatory and investor focus is on durable response and safety.